Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
LongBio Pharma (Suzhou) and Dajin Heavy Industry kick off bookbuilding for Hong Kong IPO
Hong Kong welcomes two Chinese firms to kick off their bookbuilding for listing in Hong Kong on Thursday. SCROLL TO CONTINUE WITH CONTENT LongBio Pharma (Suzhou), a clinical-stage Chinese biopharmaceutical startup, plans to offer 14.19 million H…
Ascendis Pharma: Rare Endocrine Compounder Entering Growth Phase
Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage…
Exclusive: Solstice raises $21M for pharma marketing
Axios Pro Exclusive Content 2 hours ago…
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
HERZLIYA, Israel and CALGARY, AB, May 27, 2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the 'Company' or 'Innocan'), a pharmaceutical technology company focusing on developing innovative drug delivery platform…
Eli Lilly Crosses $1 Milestone Valuation To Become Pharma's First Ever Trillion-Dollar Company
Eli Lilly and Company (NYSE: LLY) has made Wall Street history as the first pharmaceutical company to reach a $1 trillion market capitalization. The company's stock surged to record highs above $1,000 per share, cementing its position as one of the…
LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO
New hospital contracts and retail listings for Steri-Med Pharma ophthalmic products expected to generate more than $4 million in recurring annual revenues. Alain R. Dugal appointed Executive Vice-President & Chief Operating Officer to lead…
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $98.00
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price objective lifted by analysts at Morgan Stanley from $94.00 to $98.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an 'overweight' rating on the stock.
Swedbank AB Takes Position in BridgeBio Pharma, Inc. $BBIO
Swedbank AB bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 27,600 shares of the company's…
Swedbank AB Buys Shares of 90,900 NewAmsterdam Pharma Company N.V. $NAMS
Swedbank AB bought a new stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 90,900 shares…
HC Wainwright Reiterates 'Buy' Rating for BridgeBio Pharma (NASDAQ:BBIO)
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report)'s stock had its 'buy' rating reissued by HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $110.00 target price on the stock. HC Wainwright's price…
232,401 Shares in BridgeBio Pharma, Inc. $BBIO Acquired by Fisher Asset Management LLC
Fisher Asset Management LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm…
Seven Grand Managers LLC Invests $3.82 Million in BridgeBio Pharma, Inc. $BBIO
Seven Grand Managers LLC bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 50,000…
People Are Revealing The Billion-Dollar Industries That Actually Provide No Real Value To Society
'Catastrophe storm claims adjusters. These people literally destroy the insurance companies with their reports on how much damage a storm has done, and in turn, it gets pushed into everyone's insurance premiums. The insurance companies already have…
Why The Next Era Of Biomanufacturing Will Be Won By Intelligence
Dr. Hamid Noori is the CEO of The Cultivated B. As a scholar, he conducted his work at Princeton, MIT, Max Planck Society and IHES. Talk to anyone who has spent time on a biomanufacturing floor of a pharmaceutical company, and you will eventually…
Three Companies Seeking to Raise Up to $1B, Joining Hong Kong Listing Wave
The largest of the three offerings is likely to be by Dajin Heavy Industry, which aims to raise up to 5.77 billion Hong Kong dollars, equivalent to US$736.4 million, through the sale of nearly 87.0 million shares at a maximum price of HK$66.40…
Receive a Daily briefing on Pharma Industry News
Get Started